RAPID MICRO BIOSYSTEMS, INC. 8-K

What Happened

• On March 12, 2026, Rapid Micro Biosystems, Inc. (RPID) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results are provided in a press release attached to the 8-K as Exhibit 99.1.
• On the same date the company also announced a new multi-system order from Samsung Biologics for its Growth Direct platform, disclosed in a separate press release attached as Exhibit 99.2. Both press releases were furnished with the Form 8-K (not “filed” for Section 18 liability or incorporation by reference).

Key Details

• Date of filings and announcements: March 12, 2026.
• Reporting period: fourth quarter and fiscal year ended December 31, 2025 (financial results disclosed in Exhibit 99.1).
• Commercial update: new multi-system order from Samsung Biologics for the Growth Direct platform (described in Exhibit 99.2).
• Administrative: materials furnished on the Form 8‑K; signed by CFO Sean Wirtjes.

Why It Matters

• Earnings/financial results release: investors should review the attached press release for revenue, earnings, guidance, and other quarterly results that affect valuation and near-term outlook.
• Commercial traction: a multi‑system order from a major contract manufacturer like Samsung Biologics signals potential revenue contribution and customer adoption of the Growth Direct platform; the filing confirms the order but does not disclose dollar amounts or timing.
• Legal/formal note: the company furnished (rather than filed) these press releases on Form 8‑K, which affects incorporation and liability—investors should consult the exhibits for full details and figures.